retatrutide nonalcoholic steatohepatitis trial fatty liver disease nash A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis NASH Study | Fatty Liver

Smaller portions, higher protein, and functional ingredients are quickly becoming baseline expectations across the food industry

Notably, 77.1% achieved and maintained at least 5% weight loss over the full study period

For a broader comparison of side effect profiles, our three-way comparison guide covers the key differences

These include: Nausea Vomiting Diarrhea Constipation Headaches Fatigue Dizziness Loss of appetite Changes in how food tastes These side effects tend to improve over time, especially if you start with a lower dose and increase slowly

Gaucher, a rare disease affecting about one in every 50,000 people in the world population and up to one in 500 people in people of Ashkenazi (eastern and central European) Jewish heritage

Prescribing outside the licensed indications and doses constitutes off-label use, which requires prescribers to document their rationale, obtain informed consent, and provide appropriate monitoring